News
Revenues +11.6%, Adjusted EBITDA +13.1% - Organic development compared to pro forma figures Q1 2024: revenues -6.5%, adjusted EBITDA -9.3% - Q1 significantly influenced by revenue shift in syringe ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback